News & Updates
Filter by Specialty:
Brolucizumab noninferior to aflibercept in nAMD
Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.
Brolucizumab noninferior to aflibercept in nAMD
03 Sep 2022
Liraglutide boosts lipid metabolism in T2DM, but comes with more side effects
Compared with dapagliflozin, the glucagon-like peptide 1 liraglutide induces better lipid metabolism in patients with type 2 diabetes mellitus (T2DM), a recent study has found. However, this drug also comes with more adverse events than its sodium-glucose co-transporter 2 inhibitor comparator.
Liraglutide boosts lipid metabolism in T2DM, but comes with more side effects
02 Sep 2022
Could tixagevimab–cilgavimab prevent progression to severe COVID-19 in unvaccinated adults?
The combination of tixagevimab and cilgavimab, two SARS-CoV-2 neutralizing monoclonal antibodies, appeared to protect against progression to severe disease or death in non-hospitalized, unvaccinated adults presenting with mild-to-moderate COVID-19, results of the ongoing phase III TACKLE trial showed.